Compare Consolidated Edison, Inc. (ED) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Consolidated Edison, Inc. vs Viatris Inc — how do they compare? Consolidated Edison, Inc. trades at $107.69 (market cap $39.76B), while Viatris Inc trades at $16.21 (market cap $18.69B). The key difference: Consolidated Edison, Inc. is far larger — about 2.1× Viatris Inc's market cap, and Consolidated Edison, Inc. pays the higher dividend (3.27%). Which is the better fit depends on your goals.
| ED | VTRS | |
|---|---|---|
Market Cap | $39.76B | $18.69B |
Sector | Utilities | Health |
52-Week High | $115.46 | $17.86 |
52-Week Low | $95.37 | $9.49 |
Enterprise Value | $66.61B | $30.80B |
Dividend Yield | 3.27% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Consolidated Edison (ED) trades at $106.3, down 1.56% today, near the consensus price target of $103.25. Recent Q2 2026 earnings beat estimates with EPS of $0.83, though Q1 missed. The stock shows a bearish technical trend with support at $105 and resistance at $108. Fundamentals are stable with 2025 revenue of $16.92B and net income margin of 12.53%, supported by consistent dividend payments.
ED offers steady income with a 3.2% dividend yield and regulated utility stability, but faces headwinds from high debt levels and mixed analyst sentiment (62.96% hold rating). Key risks include interest rate sensitivity and capital expenditure demands for grid upgrades. The stock suits defensive investors seeking reliable dividends amid moderate growth expectations.
Viatris (VTRS) trades at $16.28, down 0.91% on the day, with a bearish technical signal and mixed fundamentals. The company reported a net loss of $3.51 billion in 2025 despite recent quarterly earnings beats, including Q2 2026 EPS of $0.69 versus $0.62 expected. Revenue declined to $14.30 billion in 2025, but operational cash flow remains strong at $2.32 billion. Recent news highlights divestitures and FDA approval for Gwyn Lo, a contraceptive patch.
Outlook is cautious due to persistent losses and high P/E of 236.2, but dividend payments and cost-cutting efforts offer stability. Risks include competitive pressures and debt levels, while analyst consensus leans hold. The stock's value hinges on margin improvement and debt reduction progress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Consolidated Edison, Inc.
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities will generate nearly all of Con Ed's earnings once it closes the sale of its clean energy business to RWE. Con Ed's clean energy business owns the second-largest portfolio of utility-scale solar projects in the U.S. Following the sale, Con Ed's only non-utility earnings will come from investments in gas and electric transmission.
Read more on ED →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
